Kate Lawrenson

ORCID: 0000-0002-6469-2515 · 46 papers in corpus
other 2020
Nature communications ·doi:10.1038/s41467-020-15951-0

The functional consequences of somatic non-coding mutations in ovarian cancer (OC) are unknown. To identify regulatory elements (RE) and genes perturbed by acquired non-coding variants, here we establish epigenomic and transcriptomic landsc…

other 2020
American journal of human genetics ·doi:10.1016/j.ajhg.2020.08.021

Quantifying the functional effects of complex disease risk variants can provide insights into mechanisms underlying disease biology. Genome-wide association studies have identified 39 regions associated with risk of epithelial ovarian cance…

other 2019
Cancer research ·doi:10.1158/0008-5472.can-17-3864

Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and asse…

review 2019
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2018-01869

CONTEXT: Infertility affects 10% of the reproductive-age population. Even the most successful treatments such as assisted reproductive technologies still result in failed implantation. In addition, adverse pregnancy outcomes associated with…

other 2019
Gynecologic Oncology ·doi:10.1016/j.ygyno.2019.10.021

OBJECTIVES: Peritoneal implants of ovarian borderline serous tumors are diagnostically challenging. Distinguishing invasive from non-invasive cases is crucial for patient management. This study aims to develop a molecular signature to disti…

lab-animal 2018
PloS one ·doi:10.1371/journal.pone.0196913

Exosomes are endosome-derived membrane vesicles that contain proteins, lipids, and nucleic acids. The exosomal transcriptome mediates intercellular communication, and represents an understudied reservoir of novel biomarkers for human diseas…

other 2017
Oncotarget ·doi:10.18632/oncotarget.16781

Gene fusions play a critical role in some cancers and can serve as important clinical targets. In epithelial ovarian cancer (EOC), the contribution of fusions, especially by histological type, is unclear. We therefore screened for recurrent…

lab-animal 2017
Cancer letters ·doi:10.1016/j.canlet.2017.04.040

The chromatin remodeler AT-Rich Interactive Domain 1A (ARID1A) is frequently mutated in ovarian clear cell carcinoma (OCCC) and endometriosis precursor lesions. Here, we show that knocking down ARID1A in an immortalized endometriosis cell l…

other 2017
Nature genetics ·doi:10.1038/ng.3826

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptib…

other 2016
Oncogenesis ·doi:10.1038/oncsis.2016.54

The SRC proto-oncogene is commonly overexpressed or activated during cancer development. Src family kinase inhibitors are approved for the treatment of certain leukemias, and are in clinical trials for the treatment of solid tumors. Src sig…

lab-animal 2015
Human molecular genetics ·doi:10.1093/hmg/ddv101

Understanding the regulatory landscape of the human genome is a central question in complex trait genetics. Most single-nucleotide polymorphisms (SNPs) associated with cancer risk lie in non-protein-coding regions, implicating regulatory DN…

observational 2015
Journal of genetics and genome research ·doi:10.23937/2378-3648/1410017

Disruption in circadian gene expression, whether due to genetic variation or environmental factors (e.g., light at night, shiftwork), is associated with increased incidence of breast, prostate, gastrointestinal and hematologic cancers and g…

2015
Nature genetics ·doi:10.1038/ng.3185

Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After…

other 2015
PloS one ·doi:10.1371/journal.pone.0130909

BACKGROUND: The molecular biology and cellular origins of mixed type endometrial carcinomas (MT-ECs) are poorly understood, and a Type II component of 10 percent or less may confer poorer prognoses. METHODOLOGY/PRINCIPAL FINDINGS: We studi…

lab-animal 2015
International journal of cancer ·doi:10.1002/ijc.29092

Most solid tumors contain cancer-associated fibroblasts (CAFs) that support tumorigenesis and malignant progression. However, the cellular origins of CAFs in epithelial ovarian cancers (EOCs) remain poorly understood, and their utility as a…

lab-animal 2014
Journal of ovarian research ·doi:10.1186/1757-2215-7-17

BACKGROUND: Endometriosis is characterized by the presence of functional endometrial tissue outside of the uterine cavity. It affects 1 in 10 women of reproductive age. This chronic condition commonly leads to consequences such as pelvic pa…

lab-animal 2014
Gynecologic Oncology ·doi:10.1016/j.ygyno.2014.06.016

BACKGROUND: Endometriosis is a common condition that is associated with an increased risk of developing ovarian carcinoma. Improved in vitro models of this disease are needed to better understand how endometriosis, a benign disease, can und…

other 2013
Nature communications ·doi:10.1038/ncomms2629

HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic silencing in serous epithelial ovarian cancer, leading us to hypothesize that variation in this gene differentially associates with epithelial ovaria…

lab-animal 2013
BMC cell biology ·doi:10.1186/1471-2121-14-43

BACKGROUND: Fallopian tube secretory epithelial cells (FTSECs) have been implicated as a cell-of-origin for high-grade serous epithelial ovarian cancer. However, there are relatively few in vitro models of this tissue type available for use…

lab-animal 2012
Journal of visualized experiments : JoVE ·doi:10.3791/4206

Epithelial ovarian cancers (EOCs) are the leading cause of death from gynecological malignancy in Western societies. Despite advances in surgical treatments and improved platinum-based chemotherapies, there has been little improvement in EO…

other 2009
PLoS medicine ·doi:10.1371/journal.pmed.1000025

Kate Lawrenson and Simon Gayther discuss two studies of ovarian cancer inPLoS Medicine, one on clinico-pathological heterogeneity and one on gene expression profiling.